4,241 Shares in Sanofi (NASDAQ:SNY) Acquired by Portfolio Design Labs LLC

Portfolio Design Labs LLC purchased a new stake in Sanofi (NASDAQ:SNY) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 4,241 shares of the company’s stock, valued at approximately $205,000.

Other hedge funds have also added to or reduced their stakes in the company. AQR Capital Management LLC bought a new position in Sanofi in the 2nd quarter valued at about $344,000. Koshinski Asset Management Inc. acquired a new position in shares of Sanofi in the third quarter valued at approximately $211,000. Creative Planning increased its stake in shares of Sanofi by 18.0% during the third quarter. Creative Planning now owns 220,763 shares of the company’s stock worth $12,723,000 after purchasing an additional 33,728 shares during the period. Regatta Capital Group LLC lifted its holdings in Sanofi by 1.7% during the 3rd quarter. Regatta Capital Group LLC now owns 16,611 shares of the company’s stock worth $957,000 after purchasing an additional 274 shares during the last quarter. Finally, Asset Dedication LLC boosted its stake in Sanofi by 284.1% in the 3rd quarter. Asset Dedication LLC now owns 3,902 shares of the company’s stock valued at $225,000 after purchasing an additional 2,886 shares during the period. Institutional investors and hedge funds own 14.04% of the company’s stock.

Sanofi Price Performance

Shares of NASDAQ SNY opened at $54.56 on Thursday. The stock has a market capitalization of $138.46 billion, a PE ratio of 21.91, a P/E/G ratio of 0.99 and a beta of 0.57. Sanofi has a fifty-two week low of $45.22 and a fifty-two week high of $58.97. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 0.74. The business has a fifty day moving average price of $50.07 and a two-hundred day moving average price of $52.41.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings data on Thursday, January 30th. The company reported $0.70 earnings per share for the quarter, hitting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.58%. As a group, equities analysts predict that Sanofi will post 4.36 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have weighed in on SNY shares. Deutsche Bank Aktiengesellschaft upgraded Sanofi from a “sell” rating to a “hold” rating in a research report on Thursday, January 30th. StockNews.com lowered shares of Sanofi from a “buy” rating to a “hold” rating in a research report on Thursday, December 12th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has issued a buy rating and two have issued a strong buy rating to the company. Based on data from MarketBeat, Sanofi has an average rating of “Buy” and an average target price of $60.00.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.